Clinical Trial Update: Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World

View source ↗

Summary

A completed real-world study evaluating the effect of semaglutide on cardiovascular outcomes in adults with overweight or obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Obesity

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Overweight, Obesity | Status: COMPLETED